Skip to main content

Advertisement

SpringerLink
Log in

Higher risk of Parkinson disease in patients with primary Sjögren’s syndrome

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Objective

This study assessed the risk of Parkinson disease (PD) in patients with primary Sjögren’s syndrome (pSS) using a nationwide, population-based cohort during a 15-year follow-up period.

Method

We identified 17,028 patients with pSS by using the catastrophic illness registry in the Taiwan National Health Insurance Research Database, and 68,094 matched non-pSS controls.

Results

The pSS cohort showed a higher incidence of PD development than did the non-pSS cohort (1.60% vs. 1.17%, p = 0.0001). The adjusted hazard ratio (aHR) of developing PD was 1.23 times greater in the pSS group than in the non-pSS group. When stratified by sex, age, and comorbidities, the female patients with pSS and patients aged between 61 and 70 years were associated with a higher PD risk (aHR 1.28 and aHR 1.30, respectively). Patients with pSS with no other comorbidity had a higher risk of PD (aHR: 2.17), compared with the non-pSS patients with no other comorbidity. When comparing non-pSS patients without or with comorbidity with pSS without or with comorbidity, pSS patients with comorbidity had highest risk of PD (aHR: 3.814).

Conclusions

All of the above findings suggested that pSS is an independent risk factor for the development of PD.

Key Points

•The patients with pSS had 1.23 times risk of Parkinson disease than the non-pSS group.

•The female patients with pSS and patients aged between 61 and 70 years were associated with a higher PD risk (aHR 1.28 and aHR 1.30, respectively).

•The pSS patients with comorbidity had highest risk of PD (aHR: 3.814).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Kapoor S (2014) Parkinsonism: an under-recognized neurological complication of Sjogren's syndrome. J Neurol Sci 338:235. https://doi.org/10.1016/j.jns.2013.12.014

    Article  PubMed  Google Scholar 

  2. Poewe W, Seppi K, Tanner CM, Halliday GM, Brundin P, Volkmann J, Schrag AE, Lang AE (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https://doi.org/10.1038/nrdp.2017.13

    Article  PubMed  Google Scholar 

  3. Hirsch EC, Hunot S (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8:382–397. https://doi.org/10.1016/S1474-4422(09)70062-6

    Article  PubMed  CAS  Google Scholar 

  4. Wang Q, Liu Y, Zhou J (2015) Neuroinflammation in Parkinson's disease and its potential as therapeutic target. Transl Neurodegener 4:19. https://doi.org/10.1186/s40035-015-0042-0

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  5. Carvajal Alegria G, Guellec D, Mariette X, Gottenberg JE, Dernis E, Dubost JJ, Trouvin AP, Hachulla E, Larroche C, le Guern V, Cornec D, Devauchelle-Pensec V, Saraux A (2016) Epidemiology of neurological manifestations in Sjogren's syndrome: data from the French ASSESS Cohort. RMD Open 2:e000179. https://doi.org/10.1136/rmdopen-2015-000179

    Article  PubMed  PubMed Central  Google Scholar 

  6. Visser LH, Koudstaal PJ, van de Merwe JP (1993) Hemiparkinsonism in a patient with primary Sjogren's syndrome. A case report and a review of the literature. Clin Neurol Neurosurg 95:141–145

    Article  CAS  PubMed  Google Scholar 

  7. Cebrian C, Loike JD, Sulzer D (2015) Neuroinflammation in Parkinson's disease animal models: a cell stress response or a step in neurodegeneration? Curr Top Behav Neurosci 22:237–270. https://doi.org/10.1007/7854_2014_356

    Article  PubMed  CAS  Google Scholar 

  8. Gagne JJ, Power MC (2010) Anti-inflammatory drugs and risk of Parkinson disease: a meta-analysis. Neurology 74:995–1002. https://doi.org/10.1212/WNL.0b013e3181d5a4a3

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  9. Rocha NP, de Miranda AS, Teixeira AL (2015) Insights into neuroinflammation in Parkinson's disease: from biomarkers to anti-inflammatory based therapies. Biomed Res Int 2015:628192. https://doi.org/10.1155/2015/628192

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  10. Thakur P, Nehru B (2015) Inhibition of neuroinflammation and mitochondrial dysfunctions by carbenoxolone in the rotenone model of Parkinson's disease. Mol Neurobiol 51:209–219. https://doi.org/10.1007/s12035-014-8769-7

    Article  PubMed  CAS  Google Scholar 

  11. Wu MC, Xu X, Chen SM, Tyan YS, Chiou JY, Wang YH, Lin LC, Chen CM, Wei JC (2017) Impact of Sjogren's syndrome on Parkinson's disease: a nationwide case-control study. PLoS One 12:e0175836. https://doi.org/10.1371/journal.pone.0175836

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  12. Chang CC, Lin TM, Chang YS, Chen WS, Sheu JJ, Chen YH, Chen JH (2018) Autoimmune rheumatic diseases and the risk of Parkinson disease: a nationwide population-based cohort study in Taiwan. Ann Med 50:83–90. https://doi.org/10.1080/07853890.2017.1412088

    Article  PubMed  CAS  Google Scholar 

  13. Ju UH, Liu FC, Lin CS, Wen-Yen Huang WY et al (2019) Risk of Parkinson disease in Sjögren syndrome administered ineffective immunosuppressant therapies: a nationwide population-based study. Medicine 98:14. https://doi.org/10.1097/MD.0000000000014984

    Article  CAS  Google Scholar 

  14. Cheng TM (2015) Reflections on the 20th anniversary of Taiwan's single-payer National Health Insurance System. Health Aff (Millwood) 34:502–510. https://doi.org/10.1377/hlthaff.2014.1332

    Article  Google Scholar 

  15. Weng MY, Huang YT, Liu MF, Lu TH (2011) Incidence and mortality of treated primary Sjogren's syndrome in Taiwan: a population-based study. J Rheumatol 38:706–708. https://doi.org/10.3899/jrheum.100883

    Article  PubMed  Google Scholar 

  16. Garcia-Carrasco M et al (2002) Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients. Medicine (Baltimore) 81:270–280

    Article  Google Scholar 

  17. Morgen K, McFarland HF, Pillemer SR (2004) Central nervous system disease in primary Sjogrens syndrome: the role of magnetic resonance imaging. Semin Arthritis Rheum 34:623–630

    Article  PubMed  Google Scholar 

  18. Hassin-Baer S, Levy Y, Langevitz P, Nakar S, Ehrenfeld M (2007) Anti-beta2-glycoprotein I in Sjogren's syndrome is associated with parkinsonism. Clin Rheumatol 26:743–747. https://doi.org/10.1007/s10067-006-0398-8

    Article  PubMed  Google Scholar 

  19. Kobayashi S, Yamaguchi S, Suzuki T, Yamauchi K, Tsunematsu T (1986) Central nervous system involvement in primary Sjogren's syndrome. Rinsho Shinkeigaku 26:1009–1016

    PubMed  CAS  Google Scholar 

  20. Mochizuki H, Okano M, Masaki T, Nagata N, Kamakura K (1997) A case of Sjogren's syndrome with a high titer of anticardiolipin antibody that developed as parkinsonism. Rinsho Shinkeigaku 37:57–59

    PubMed  CAS  Google Scholar 

Download references

Funding

This study received support from Wan Fang Hospital and Taipei Medical University (108TMU-WFH-20, DP2-108-21121-01-I-12).

Author information

Author notes

  1. Hui-Ching Hsu and Tsung-Yun Hou contributed equally to this work.

Authors and Affiliations

  1. Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan

    Hui-Ching Hsu & Tsung-Yun Hou

  2. Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, 252 Wu-Hsing Street, Taipei, 11031, Taiwan

    Hui-Ching Hsu, Tsung-Yun Hou, Tzu-Min Lin, Yu-Sheng Chang & Chi-Ching Chang

  3. Division of Rheumatology/Immunology/Allergy, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

    Tsung-Yun Hou

  4. Division of Rheumatology, Immunology and, Allergy, Department of Internal Medicine, Taipei Medical University Hospital, Taipei, Taiwan

    Tzu-Min Lin, Pei-I Kuo & Chi-Ching Chang

  5. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Shuang Ho Hospital, Taipei Medical University, New Taipei City, Taiwan

    Yu-Sheng Chang

  6. Division of Allergy, Immunology, and Rheumatology, Department of Internal Medicine, Taipei Veterans General Hospital, National Yang-Ming University, Taipei, Taiwan

    Wei-Sheng Chen

  7. Biostatistics Center, College of Management, Taipei Medical University, Taipei, Taiwan

    Yi-Chun Lin & Jin Hua Chen

  8. Graduate Institute of Data Science, College of Management, Taipei Medical University, Taipei, Taiwan

    Jin Hua Chen

  9. Biostatistics Center and School of Public Health, Taipei Medical University, 252, Wu-Hsing Street, Taipei, 11031, Taiwan

    Jin Hua Chen

Authors
  1. Hui-Ching Hsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Tsung-Yun Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tzu-Min Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yu-Sheng Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei-Sheng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Pei-I Kuo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Yi-Chun Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chi-Ching Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Jin Hua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Hui-Ching Hsu and Tsung-Yun Hou contributed to study conception and design, article drafting, critical article revision for crucial intellectual content, and the final approval of the submitted version. Tzu-Min Lin and Yu-Sheng Chang contributed to data interpretation, critical article revision for crucial intellectual content, and the final approval of the submitted version. Wei-Sheng Chen and Pei-i Kuo contributed to data analysis, critical article revision for crucial intellectual content, and the final approval of the submitted version. Yi-Chun Lin contributed to data analysis, article drafting, and the final approval of the submitted version. Chi-Ching Chang and Jin-Hua Chen was responsible for study conception and design, complete data analysis, critical article revision for crucial intellectual content, and correspondence for the final approval of the submitted version.

Corresponding authors

Correspondence to Chi-Ching Chang or Jin Hua Chen.

Ethics declarations

Disclosures

None.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hsu, HC., Hou, TY., Lin, TM. et al. Higher risk of Parkinson disease in patients with primary Sjögren’s syndrome. Clin Rheumatol 39, 2999–3007 (2020). https://doi.org/10.1007/s10067-020-05053-z

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-020-05053-z

Keywords

Search

Navigation